Luteolin as a Cancer Therapeutic: From Preclinical Evidence to Translational Potential
- 15 August 2026
- journal article
- review article
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (8) , e71590
Abstract
Cancer, a condition marked by the atypical development and multiplication of cells that may acquire aggressive properties, ranks among the foremost causes of mortality globally. Because of the problems with existing chemotherapy medications, cancer therapeutic research is being conducted to find substitute treatment approaches that are less harmful to healthy cells. The application of flavonoids has become a prominent area of interest in cancer therapy research. Luteolin, 3′,4′,5,7‐tetrahydroxyflavone, is a common flavonoid that may be found in many plants and medicinal herbs. Luteolin‐rich plants have been used to cure a variety of illnesses, including cancer, inflammatory conditions, and hypertension. Targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression, luteolin's anticancer properties have been thoroughly studied in a variety of cancer types. It interacts with several proteins and signaling pathways to accomplish this. The development of contemporary luteolin research is outlined in this study, with an emphasis on preclinical data and translational prospects. This article reveals the chemistry, structure–activity relationship, and extraction techniques of luteolin. It explores pharmacological activities, mechanism of action, and advancements in nanoformulation strategies. Furthermore, it explains how luteolin's potential as a cancer treatment is demonstrated from preclinical proof to translational capability.Keywords
This publication has 104 references indexed in Scilit:
- Role of Luteolin in Prevention of Oral, Esophageal, Gastric, Pancreatic, and Colon Cancers: Recent Trends and Future PerspectivesJournal of Biochemical and Molecular Toxicology, 2026
- The Novel Approaches to Extraction Techniques, Drug Delivery Technologies, Pharmacological Applications, Patents of the Potent Flavonoid ‘Luteolin’: An AppraisalChemistry & Biodiversity, 2025
- Paclitaxel/Luteolin Coloaded Dual‐Functional Liposomes for Esophageal Cancer TherapyAdvanced Science, 2025
- Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human MalignanciesFood Science & Nutrition, 2025
- Structure–Activity Relationship Between Flavonoids and Chronic Metabolic Diseases2024
- Flavonoids as promising anticancer therapeutics: Contemporary research, nanoantioxidant potential, and future scopePhytotherapy Research, 2023
- Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeuticsMedicinal Research Reviews, 2022
- Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulatedPhytotherapy Research, 2021
- Intestinal anti‐inflammatory activity of luteolin: Role of the aglycone in NF‐κB inactivation in macrophages co‐cultured with intestinal epithelial cellsBioFactors, 2013
- Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenograftsThe Prostate, 2007